CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel immunotherapy using CD1a-specific CAR T-cells to treat cortical T-cell acute lymphoblastic leukemia (coT-ALL). It aims to enhance the safety and efficacy of CAR T-cell therapy by targeting a unique antigen, addressing a critical gap in current cancer treatments for T-cell mali…
Immunotherapy has revolutionized cancer treatment over the last decade.
Adoptive cell immunotherapy with T-cells genetically redirected to a tumor-specific antigen using a chimeric antigen receptor (CAR) has achieved impressive response rates in advanced B-cell acute lymphoblastic leukemia (B-ALL). CAR T-cell strategies beyond B-cell tumors are, however, hampered by expected toxicities, owing to the lack of bona fide therapeutic and safe antigens.
Indeed, there are no immunotherapeutic therapies…
INSTITUT JOSEP CARRERAS - CERCA
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
